期刊文献+

非小细胞肺癌脑转移患者107例预后分析 被引量:7

The prognostic analysis for non-small cell lung cancer with brain metastases in 107 cases
原文传递
导出
摘要 目的 探讨不同治疗方法以及其他临床因素对非小细胞肺癌脑转移患者预后的影响.方法 对2010年1月至2011年12月在湖北医药学院附属人民医院进行治疗的107例非小细胞肺癌脑转移患者进行随访,了解其生存时间,并收集临床资料,分析各种治疗方式及临床特征对其预后的影响.结果 107例患者的平均生存期为(11.93±5.53)个月,中位生存期为11个月,6个月、1年和2年生存率分别为90.7%、41.1%和6.4%.Cox回归分析结果显示,颅外病灶控制、Karnofsky评分、靶向治疗和年龄为患者预后的独立影响因素,OR值分别为0.358(95%CI0.217 ~ 0.593)、0.302(95%CI0.182~0.502)、0.170(95%CI0.098 ~ 0.296)和1.635(95%CI1.010 ~ 2.647),均P<0.05.结论 放射治疗是非小细胞肺癌脑转移瘤的有效治疗手段,生物靶向治疗可以有效地延长生存期,另外患者的生存期还与年龄、Karnofsky评分以及颅外病灶控制情况等因素有一定关系. Objective To evaluate the clinical efficacy of different treatments on non-small cell lung cancer (NSCLC) patients with brain metastases and to explore the influential factors of the prognosis.Methods The NSCLC patients with brain metastases treated from Jan.2010 to Dec.2011 were follow-up.The survival time and influences resulted from the treatments were analyzed.Results The average survive time of these patients was (11.93±5.53) months,and the median survive time was 11 months.The 6-month,1-year and 2-year overall survival rates were 90.7 %,41.1% and 6.4 %,respectively.Multivariate analysis showed that control of extracranial lesions,Kamofsky score,target therapy and age were independent predictive factors of survival,and the OR value were 0.358 (95 % CI0.217-0.593),0.302 (95 % CI 0.182-0.502),0.170 (95 % CI 0.098-0.296) and 1.635 (95 % CI 1.010-2.647),respectively (all P 〈 0.01).Conclusions Radiation therapy is an effective treatment on non-small cell lung cancer with brain metastases.Biological target therapy can effectively improve survival.The survival time also is correlated with age,Karnofsky score and control of extracranial lesions.
出处 《肿瘤研究与临床》 CAS 2015年第3期168-170,174,共4页 Cancer Research and Clinic
关键词 非小细胞肺 脑转移 预后 影响因素 Carcinoma,non-small cell lung Brain metastases Prognosis Factors
  • 相关文献

参考文献10

二级参考文献25

  • 1AndrewsDW ScottCB SperdutoPW FlandersAE GasparLE SchellMC Werner-WasikM DemasW RyuJ BaharyJP SouhamiL RotmanM MehtaMP CurranWJJr.Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase Ⅲ resuIts of the RTOG 9508 randomised trial[J].中国神经肿瘤杂志,2004,2(3):192-192. 被引量:214
  • 2王志宇,李光,张晓萌,张宏伟,夏兵,左晓东,秦越军.颅脑X刀治疗脑转移瘤临床疗效分析[J].中华放射肿瘤学杂志,2007,16(1):38-41. 被引量:13
  • 3潘力.脑转移瘤//曹世龙.肿瘤学新理论与新技术.上海:上海科技教育出版社,1997,695-696. 被引量:1
  • 4Bobinet G, Thomas P, Bretan JL, et al. Results of phase Ⅲ study of early venus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non- small-cell lunn cancer:Groupe Francais de pneumo cancerolonie (GFPC) protocol 951. Ann Oncol, 2001,12:59. 被引量:1
  • 5Zhou C,Wu Y L,Chen G. Efficacy results from the randomised phase Ⅲ OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM),in Chinese advanced non-smallcell lung cancer (NSCLC) patients (pts) with EGFR activating mutations[J].Annals of Oncology,2010,(z8):viii1-viii12.LBA13. 被引量:1
  • 6Wu Y L,Zhou C,Chen G. First biomarker analyses from a phase Ⅲ,randomised,open-label,first-line study of erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese patients (pts) with advanced non-small-cell lung cancer (NSCLC) with EGFR activating mutations (OPTIMAL,CTONG 0802)[J].Annals of Oncology,2010,(z8):viii1-viii12.LBA14. 被引量:1
  • 7Rosell R,Gervais R,Vergnenegre A. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations:Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase Ⅲ randomized trial[J].Journal of Clinical Oncology,2011,(Suppl):Abstr7503. 被引量:1
  • 8Zhang L,Shenglin M,Song X. Efficacy,tolerability,and biomarker analyses from a phase Ⅲ,randomized,placebo-controlled,parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC;INFORM;CTONG0804)[J].Journal of Clinical Oncology,2011,(Suppl):AbstrLBA7511. 被引量:1
  • 9Paz-Ares L G,de Marinis F,Dediu M. PARAMOUNT:Phase Ⅲ study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC)[J].Journal of Clinical Oncology,2011,(Suppl):AbstrCRA7510. 被引量:1
  • 10Barlesi F,de Castro J,Dvornichenko V. AVAPERL (MO22089):Final efficacy outcomes for patients (pts) with advanced non-squamous non-small cell lung cancer (nsNSCLC) rancomised to continuation maintenance (mtc) with bevacizumab (bev) or bev+ pemetrexed (pem) after first-line (1L) bev-cisplatin (cis)-pem treatment (tx)[J].European Journal of Cancer,2011,(z2):AbstrLBA34. 被引量:1

共引文献46

同被引文献63

引证文献7

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部